Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin on vascular circulation and sodium content in type 2 diabetes
NCT02383238Phase 3Completed
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Mar 2014
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by FAU Erlangen-Nürnberg Medical Faculty. Started Mar 2014; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02383238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02383238.